11.05
-1.34%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shandong Sito Bio-technology Co
Its shares trade on Shenzhen under the ticker 300583.SZ. It has been listed since 6 January 2017. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.02bn and a net loss of CN¥73.1m. At that date it held total assets of CN¥2.96bn and shareholders' equity of CN¥1.76bn.
Shandong Sito Bio-technology Co., Ltd. provides steroidal pharmaceutical raw materials using biotechnology. The company is headquartered in Heze, Shandong. The company went IPO on 2017-01-06. The firm operates three product segments. The Steroid Raw Materials segment is engaged in the manufacturing of steroid raw materials using genetic engineering technology and microbial transformation technology, such as androstenedione, androstenedione, 9-hydroxyandrostenedione, hydroxyprogesterone and so on. The firm also operates Steroidal Finished Drug segment and Non-Steroidal Finished Drug segment through its subsidiary.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 6 Jan 2017
- Employees
- 1,317
- Website
- sitobiotech.com ↗
Leadership
Pay as last reported
- Mr. Qi MiChairman of the Board, since 2019
- Mr. Fuwen LiChief Financial Officer
- Mr. Lianbiao JinGeneral Manager
- Ms. Lu LiDeputy General Manager, Secretary of the Board, Director, since 2018
- Mr. Jianyong HeDeputy General Manager, since 2023
- Ms. Qingzhi KongDeputy General Manager
- Mr. Qihui PengDeputy General Manager
- Mr. Xusheng KongDirector
- Mr. Yaping MaDirector
- Ms. Li KangIndependent Director
- Mr. Pengfei TuIndependent Director
- Mr. Qiming ZhangIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Shandong Sito Bio-technology employs 1,317 full-time employees in Heze, CN.
- Steroid Raw Materials segment uses genetic engineering for androstenedione production.
- Three product segments include Steroid Raw Materials, Steroidal Finished Drug, and Non-Steroidal Finished Drug.
Weaknesses
- Steroid Raw Materials segment relies on genetic engineering technology for production.
- Steroidal Finished Drug segment operates through a subsidiary in Heze, CN.
- Non-Steroidal Finished Drug segment lacks detailed product information in the facts.
Opportunities
- Steroid Raw Materials segment targets androstenedione and hydroxyprogesterone markets.
- Steroidal Finished Drug segment expands through subsidiary operations in Heze.
- Non-Steroidal Finished Drug segment can leverage existing infrastructure for growth.
Threats
- Steroid Raw Materials segment faces competition in androstenedione market.
- Steroidal Finished Drug segment may encounter regulatory challenges in Heze.
- Non-Steroidal Finished Drug segment lacks market data for strategic planning.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.